| Hazard Information | Back Directory | [Uses]
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment. | [References]
[1] Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. DOI:10.1056/NEJMoa1607141
[2] Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80. DOI:10.1016/j.npep.2018.07.003
[3] Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284. DOI:10.1007/s40265-018-0871-0 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|